{"title": "Novavax COVID-19 Vaccine Found to be Safe and Effective in Phase 3 Trial Conducted by UM School of Medicine Researchers", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2016-06-29", "cleaned_text": "December 16, 2021 | [Deborah Kotz](mailto:dkotz@som.umaryland.edu) Contact Deborah Kotz University of Maryland Medicine dkotz@som.umaryland.edu (410) 706-4255 Related stories Tuesday, December 20, 2022 [COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds](https://www.medschool.umaryland.edu/news/2022/COVID-Vaccines-Prevented-3-Million-Deaths-in-the-US-New-Analysis-Finds.html) In the two years since the first COVID-19 vaccines were given to patients in the U.S., the vaccines had the cumulative effect of preventing 18 million hospitalizations and 3 million deaths. That is based on a new modeling analysis conducted by a researcher at the University of Maryland School of Medicine (UMSOM) and her colleagues. Results of the analysis were published by the Commonwealth Fund. Wednesday, February 16, 2022 [Study Shows New Drug Combination More Effective Against SARS-CoV-2](https://www.medschool.umaryland.edu/news/2022/Study-Shows-New-Drug-Combination-More-Effective-Against-SARS-CoV-2.html) Researchers at the University of Maryland School of Medicine (UMSOM) and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19. The researchers showed that combining the experimental drug brequinar with either of the two drugs already approved by the U.S. Food and Drug Administration for emergency use, remdesivir or molnupiravir, inhibited growth of the SARS-CoV-2 virus in human lung cells and in mice. Their findings suggest that these drugs are more potent when used in combination than individually. Wednesday, January 26, 2022 [Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of \"Mix-and-Match\" COVID-19 Vaccine Booster Dosing](https://www.medschool.umaryland.edu/news/2022/Trial-Co-led-by-University-of-Maryland-School-of-Medicine-Scientist-Confirms-Safety-of-Mix-and-Match-COVID-19-Vaccine-Booster-Dosing.html) A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person's primary vaccine(s). Tuesday, December 14, 2021 [UM School of Medicine's Office of Public Affairs and Communications Honored with 2021 PRSA 'Best In Maryland' Award ](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicines-Office-of-Public-Affairs-and-Communications-Honored-with-2021-PRSA-Best-In-Maryland-Award-.html) The University of Maryland School of Medicine (UMSOM)'s Office of Public Affairs & Communications received the Public Relations Society of America (PRSA) 2021 \"Best in Maryland Award,\" the PRSA's highest honor, for its COVID-19 Communications program. The award was given at the PRSA Maryland Gala, held on December 9, 2021. Wednesday, September 08, 2021 [UM School of Medicine Reaching Underserved Communities Through Grass Roots Efforts to Increase COVID-19 Vaccination Rates](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Reaching-Underserved-Communities-Through-Grass-Roots-Efforts-to-Increase-COVID-19-Vaccination-Rates.html) In an effort to increase COVID-19 vaccination rates among children and families, and ultimately help bring the pandemic under control, the Department of Family & Community Medicine (DFCM) and the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM) are partnering with key community and faith-based groups in Baltimore city to reach the most vulnerable and underserved communities. This partnership will also extend across Maryland, Delaware, Virginia, and West Virginia. Wednesday, July 07, 2021 [UM School of Medicine Researchers Develop Two Rapid Tests for COVID-19 Using Innovative Techniques ](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Researchers-Develop-Two-Rapid-Tests-for-COVID-19-Using-Innovative-Techniques-.html) Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods. Wednesday, June 09, 2021 [Global Study of Microbes in 60 Cities Finds Each Has Unique Fingerprint of Viruses and Bacteria](https://www.medschool.umaryland.edu/news/2021/Global-Study-of-Microbes-in-60-Cities-Finds-Each-Has-Unique-Fingerprint-of-Viruses-and-Bacteria.html) Each city has its own unique microbiome, a \"fingerprint\" of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell. Tuesday, March 16, 2021 [New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel](https://www.medschool.umaryland.edu/news/2021/New-Study-Finds-Healthcare-Settings-Do-Not-Pose-Added-Risk-Factor-for-Covid-19-Infection-Spread-Among-US-Healthcare-Personnel.html) Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities. Thursday, January 21, 2021 [UM School of Medicine Hosted Media Availability for Ensuring Trust in COVID-19 Vaccine Event](https://www.medschool.umaryland.edu/news/2021/UM-School-of-Medicine-Hosted-Media-Availability-for-Ensuring-Trust-in-COVID-19-Vaccine-Event.html) On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and \"America's Doctor,\" Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research. Tuesday, January 05, 2021 [Dr. Kathleen Neuzil, World-renowned Leader in Moderna Vaccine](https://www.medschool.umaryland.edu/news/2020/Dr-Kathleen-Neuzil-World-renowned-Leader-in-Vaccine-Research-Receives-Moderna-Vaccine.html) Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine's (UMSOM)'s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December. Tuesday, January 05, 2021 [University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate](https://www.medschool.umaryland.edu/news/2020/University-of-Maryland-School-of-Medicine-Begins-Phase-3-Trial-of-Novavax-COVID-19-Vaccine-Candidate.html) Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD. Thursday, November 19, 2020 [Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine](https://www.medschool.umaryland.edu/news/2020/Promising-Results-Seen-in-PfizerBioNTech-COVID-19-Vaccine-After-Phase-1-Trial-by-University-of-Maryland-School-of-Medicine.html) Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19. Friday, November 13, 2020 [UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-and-School-of-Pharmacy-Researchers-Identify-Promising-New-Compounds-to-Potentially-Treat-Novel-Coronaviruses.html) Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal. Tuesday, June 16, 2020 [UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Receive-Federal-Funding-to-Rapidly-Test-New-Treatments-for-COVID-19.html) Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government's Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort. Tuesday, June 02, 2020 [UM School of Medicine's Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicines-Institute-of-Human-Virology-Awarded-Grants-to-Strengthen-COVID-19-Response-in-Sub-Saharan-Africa.html) The Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine's Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique. Monday, June 01, 2020 [In A COVID-19 World, Another Threat to the Health of Our Children](https://www.medschool.umaryland.edu/news/2020/In-A-COVID-19-World-Another-Threat-to-the-Health-of-Our-Children.html) In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations. Thursday, May 28, 2020 [UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Develop-Experimental-Rapid-COVID-19-Test-Using-Innovative-Nanoparticle-Technique.html) Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society's nanotechnology journal ACS Nano. Thursday, May 21, 2020 [UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Begins-First-Innovative-Trial-of-Experimental-Stem-Cell-Therapy-to-Reduce-Deaths-in-Sickest-COVID-19-Patients.html) Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC. Tuesday, May 05, 2020 [UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-is-First-in-US-to-Test-Unique-RNA-Vaccine-Candidate-for-COVID-19.html) In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine. Thursday, April 23, 2020 [UM School of Medicine Researchers Test Remdesivir as Potential Therapy for COVID-19 Patients](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Researchers-Test-Remdesivir-as-Potential-Therapy-for-COVID-19-Patients.html) Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Friday, April 10, 2020 [University of Maryland School of Medicine Launches New Large Scale COVID-19 Testing Initiative](https://www.medschool.umaryland.edu/news/2020/University-of-Maryland-School-of-Medicine-Launches-New-Large-Scale-COVID-19-Testing-Initiative.html) University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland. Thursday, January 09, 2020 [UM School of Medicine Research Shows Less Severe Cases of Diarrheal Illness can Still Lead to Child Deaths, Even Weeks Following Onset of the Illness](https://www.medschool.umaryland.edu/news/2020/UM-School-of-Medicine-Research-Shows-Less-Severe-Cases-of-Diarrheal-Illness-can-Still-Lead-to-Child-Deaths-Even-Weeks-Following-Onset-of-the-Illness.html) Diarrheal diseases are a leading cause of death for young children, accounting for nine percent of all deaths worldwide in children under five years of age, with most occurring in children under two years of age. Now, researchers at the University of Maryland School of Medicine (UMSOM) found that even milder cases of diarrheal diseases can lead to death in young children. Monday, May 06, 2019 [UM School of Medicine's Dr. Karen Kotloff Receives 2019 Alumni Achievement Award from Temple University](https://www.medschool.umaryland.edu/news/2019/UM-School-of-Medicines-Dr-Karen-Kotloff-Receives-2019-Alumni-Achievement-Award-from-Temple-University.html) Karen Kotloff, MD, Professor of Pediatrics at the University of Maryland School of Medicine (UMSOM), has received the 2019 Alumni Achievement Award from the Lewis Katz School of Medicine at Temple University. Monday, October 15, 2018 [University of Maryland School of Medicine Scientists Receive Prestigious UMB Founders Week Awards](https://www.medschool.umaryland.edu/news/2018/University-of-Maryland-School-of-Medicine-Scientists-Receive-Prestigious-UMB-Founders-Week-Awards.html) Several experts at the UMSOM received prestigious awards commemorating the UMB 2018 Founders Week. Among them, Karen Kotloff, MD, Professor of Pediatrics, was named \"Researcher of the Year\" for her extensive work in infectious diseases in the U.S. and developing countries. The MARS team - Steven I. Hanish, MD, Visiting Associate Professor of Surgery, Thomas M. Scalea, MD, FACS, FCCM, The Honorable Francis X. Kelly Distinguished Professor in Trauma Surgery, and Deborah Stein, MD, MPH, FACS, FCCM, The R Adams Cowley, MD Professor in Shock and Trauma- were named \"Entrepreneurs of the Year\" for their liver dialysis device called the Molecular Absorbent Recirculating System (MARS). Monday, September 11, 2017 [Research Identifies Causes and Possible Treatments for Deadly Diseases Affecting Children in Developing Countries](https://www.medschool.umaryland.edu/news/2017/Research-Identifies-Causes-and-Possible-Treatments-for-Deadly-Diseases-Affecting-Children-in-Developing-Countries.html) University of Maryland School of Medicine Researchers Explore How to Prevent Diarrheal Diseases, a Leading Cause of Death in Young Children in Sub-Saharan Africa and South Asia Wednesday, June 29, 2016 [UM SOM Researchers Awarded Grant to Use Innovative Alternative to Autopsies to Better Understand Child Mortality](https://www.medschool.umaryland.edu/news/2016/UM-SOM-Researchers-Awarded-Grant-to-Use-Innovative-Alternative-to-Autopsies-to-Better-Understand-Child-Mortality.html) Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that CVD has been awarded a large grant from the Bill & Melinda Gates Foundation for research that will help determine why so many children under five are dying in the world's poorest countries. The grant will fund use of an innovative alternative to traditional autopsy known as minimally invasive tissue sampling. The technique, which involves the collection of tissue samples with fine needles, allows researchers to quickly identify the cause of death, and help illuminate ways to save lives and improve the health of children in these vulnerable areas. "}